Search the Newsreel

A New Arcus Employee Receives Options With a $28.72 Exercise Price

Arcus Biosciences (NYSE: RCUS) announced that its Compensation Committee granted a new employee options to purchase 2,850 shares of common stock at an exercise price of $28.72 per share, which was the closing price on August 10, 2026. The employee also received restricted stock …

Satellos Bioscience (MSLE) sets up US$300M shelf to fund Duchenne drug

Caribou Biosciences, Inc. expected to post a loss of 32 cents a share - Earnings Preview

Caribou Biosciences, Inc. is expected to report an upcoming earnings loss. Analysts project the company to post a loss of 32 cents per share. This information is presented as an earnings preview.

Alamar Biosciences Q2 Results: Revenue Rises 82% To $29.4 Million

PLSE: nsPFA technology delivers breakthrough efficacy in AFib and is poised for broad clinical adoption

Pulse Biosciences, Inc. (PLSE) is developing next-generation nsPFA technology for AFib treatment, demonstrating high efficacy and efficiency. The company's leadership, strong clinical data, competitive position, and partnership strategy are expected to drive broad clinical adoption. This information is based on an audio transcript from …

Trade Desk, Papa John's, Emergent BioSolutions Hit 52-Week Lows as Weak Results Trigger Analyst Downgrades

Trade Desk, Papa John's, and Emergent BioSolutions all hit 52-week lows following disappointing quarterly results and subsequent analyst downgrades. Trade Desk faced a significant downgrade after missing revenue estimates and providing weak guidance, while Papa John's experienced a revenue decline despite an earnings beat. …

Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences

argenx SE (NASDAQ:ARGX) agreed to buy Forte Biosciences, Inc. (NASDAQ:FBRX) for about $2.2 billion in cash, paying $77 a share, a roughly 40% premium to Forte's Friday closing price. The deal adds Forte's experimental drug FB102, which analysts describe as a first-in-class anti-CD122 antibody, …

EBS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Emergent BioSolutions

SueWallSt, powered by Levi & Korsinsky LLP, has announced an investigation into potential securities law violations by Emergent BioSolutions (NYSE: EBS). This follows Emergent BioSolutions lowering its FY2026 adjusted EBITDA guidance and recording a significant non-cash NARCAN impairment due to increased competition and pricing …

Harvard Bioscience targets 3% to 5% full-year 2026 revenue growth as CMT and China mix shifts gross margin to 57% to 59%

Earnings Call Insights: Harvard Bioscience (HBIO) Q2 2026 MANAGEMENT VIEW * "That disciplined focus and execution helped us deliver strong second quarter performance, highlighted by double-digit revenue growth across our CMT and preclinical portfolios and solid operational execution that reinforced our confidence in raising …

Harmony Biosciences (HRMY) Q2 2026 Earnings Call Transcript

Cogent Biosciences (NASDAQ:COGT) Shares Down 5.7% - Should You Sell?

HC Wainwright Lowers Aura Biosciences (NASDAQ:AURA) Price Target to $18.00

HC Wainwright has reduced its price target for Aura Biosciences (NASDAQ:AURA) to $18.00 from $24.00, while maintaining a "Buy" rating, indicating a potential upside of 131.1% from its current price. This adjustment comes as Aura Biosciences reported a wider-than-expected quarterly loss of $0.48 per …

Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX

Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Forte Biosciences, Inc. (FBRX) to argenx SE for $77.00 per share in cash. KSF is evaluating whether this price adequately values Forte Biosciences and if the process leading to the sale was …

Stifel raises Alamar Biosciences stock price target on earnings beat

Stifel has increased its target price for ALAMAR BIOSCIENCES INC to $32 from $28. This update, reported by Reuters, reflects an analyst's revised valuation for the company. The article emphasizes that the content represents the author's opinion and should not be used as investment …

Belenos Biosciences Announces Positive Topline Results from a Phase 2 Clinical Trial of BEL512 in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

The study met its primary and all secondary endpoints at Week 24 Rapid onset of clinical activity was observed with significant improvements as early as Week 4 Durable clinical activity demonstrated following single-dose administration, supporting 6- month dosing for the treatment of CRSwNP '512 …

Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.82, Implies 94% Upside

Analysts have slightly cut the average 12-month price target for Tyra Biosciences, Inc. (TYRA) stock from $51.09 to $50.82, with individual forecasts ranging from $39 to $59. This updated target suggests a potential upside of approximately 94% based on the recent closing price. The …

Aura Biosciences (NASDAQ:AURA) Posts Quarterly Earnings Results, Misses Expectations By $0.10 EPS

* Aura Biosciences press release [https://seekingalpha.com/pr/20614282-aura-biosciences-reports-second-quarter-2026-financial-results-and-recent-business-highlights] (AURA [https://seekingalpha.com/symbol/AURA]): Q2 GAAP EPS of -$0.48 misses by $0.10. * As of June 30, 2026, Aura had cash and cash equivalents and marketable securities totaling $323.8 million. The Company believes its current cash and cash equivalents and …

Earnings Flash (ALMR) Alamar Biosciences, Inc. Reports Q2 Revenue $29.4M, Vs. FactSet Est of $25.9M

Alamar Biosciences, Inc. (ALMR) announced its second-quarter revenue of $29.4 million, significantly exceeding the FactSet estimate of $25.9 million. This earnings flash highlights the company's financial performance for the recent quarter.

Aura Biosciences Releases Q2 2026 Financial Results

Aura Biosciences, Inc. (AURA) reported a net loss of $45.6 million and a loss of $0.48 per share for Q2 2026, slightly wider than the previous year, as it continues to invest in developing precision therapies for solid tumors. Despite the losses common for …

Sagimet Biosciences (NASDAQ:SGMT) Issues Earnings Results, Beats Estimates By $0.02 EPS

Rapid Micro Biosystems (RPID) Receives a Buy from Lake Street

ALAMAR BIOSCIENCES INC : STIFEL RAISES TARGET PRICE TO $32 FROM $28

Stifel has increased its target price for ALAMAR BIOSCIENCES INC to $32 from $28. This update, reported by Reuters, reflects an analyst's revised valuation for the company. The article emphasizes that the content represents the author's opinion and should not be used as investment …

Sagimet Highlights Q2 Results and Dermatology Focus Shift

Sagimet Biosciences (SGMT) reported its Q2 2026 results, announcing a strategic pivot towards dermatology. The company plans to advance its lead FASN inhibitor, denifanstat, into a U.S. Phase 3 acne trial and progress TVB-3567, backed by $257.6 million in cash which is expected to …

HC Wainwright Issues Optimistic Estimate for PCRX Earnings

Jade Biosciences (NASDAQ:JBIO) Given New $77.00 Price Target at BTIG Research

BTIG Research has increased its price target for Jade Biosciences (NASDAQ:JBIO) to $77.00 from $74.00, reiterating a "buy" rating with a potential upside of 254.35%. Despite this, the company reported a quarterly loss of $0.76 per share, missing consensus estimates, and analysts anticipate a …

Harvard Bioscience beats estimates, raises 2026 guidance

Harvard Bioscience Inc. (NASDAQ:HBIO) surpassed analyst expectations for its second-quarter 2026 results, reporting adjusted EPS of -$0.14 and revenue of $22.7 million, exceeding estimates. The company also raised its full-year 2026 revenue guidance to 3%-5% YoY growth, citing strong demand for its telemetry and …

Aura Biosciences (AURA) doubles assets after $280.8M raise as losses mount

Aura Biosciences reported a wider net loss of $79.3 million for the first half of 2026, compared to $54.5 million in 2025, due to increased research and development and administrative expenses. Despite mounting losses, the company significantly boosted its liquidity by raising $280.8 million …

Form 8K Aura Biosciences Inc For: 11 August By Investing.com

This article is a brief financial market update from Investing.com, announcing that Aura Biosciences Inc. has filed a Form 8K on August 11. It also includes the current stock performance for AURA, showing a 4.94% increase.

Earnings Flash (AURA) Aura Biosciences Posts Q2 Net Loss $0.48 a Share, vs. FactSet Est of $0.37 Loss

Sagimet Biosciences GAAP EPS of -$0.26 in-line

* Sagimet Biosciences press release [https://seekingalpha.com/pr/20614354-sagimet-biosciences-reports-second-quarter-2026-financial-results-and-provides-corporate] (SGMT [https://seekingalpha.com/symbol/SGMT]): Q2 GAAP EPS of -$0.26 in-line. * Cash, cash equivalents and marketable securities of $257.6 million as of June 30, 2026, expected to fund current operations through 2028, including through data readout of denifanstat Phase 3 …

Sagimet Biosciences (SGMT) boosts cash to $257.6M with 2026 stock sale

Aura Biosciences GAAP EPS of -$0.48 misses by $0.10

* Aura Biosciences press release [https://seekingalpha.com/pr/20614282-aura-biosciences-reports-second-quarter-2026-financial-results-and-recent-business-highlights] (AURA [https://seekingalpha.com/symbol/AURA]): Q2 GAAP EPS of -$0.48 misses by $0.10. * As of June 30, 2026, Aura had cash and cash equivalents and marketable securities totaling $323.8 million. The Company believes its current cash and cash equivalents and …

Harvard Bioscience (HBIO) grows Q2 2026 sales but stays in loss

Harvard Bioscience (HBIO) reported an 11.1% increase in Q2 2026 revenue, reaching $22.7 million, with full-year revenue guidance raised to 3%-5% growth. Despite top-line expansion and improved gross margins, the company remains unprofitable, recording a Q2 2026 net loss of $2.9 million. Operating cash …

Aura Biosciences, Inc. Q2 2026: Net loss $45.6M, EPS $(0.48) — 10-Q Summary

Aura Biosciences, Inc. reported a Q2 2026 net loss of $45.6M, an increase from $27.0M in Q2 2025, with a diluted loss per share of $(0.48). The company remains pre-revenue but is advancing its bel-sar clinical trials, refocusing on ocular oncology, and has secured …

Aura Biosciences Reports 45.6 Million Dollar Q2 Net Loss

Aura Biosciences reported a net loss of $45.6 million for Q2 2026, an increase from $27.0 million a year prior, despite having $323.8 million in cash, cash equivalents, and marketable securities. The company announced a restructuring, including a 20% workforce reduction, to extend its …

AURA: Fully enrolled Phase 3 trial and strategic focus on ocular oncology extend cash runway to 1H 2029

Aura Biosciences (AURA) has fully enrolled its Phase 3 Compass trial for bel-sar in early choroidal melanoma, with topline data anticipated in the second half of 2027. The company's strategic shift to ocular oncology has extended its cash runway into the first half of …